

## Press Release

*8 April, 2021*

### **Pelago Bioscience AB Expands to New Facility**

After several years of continued growth in our current facilities Pelago Bioscience now really expands. The new building is located at Campus Solna, a rapidly developing Life Science cluster located in central Stockholm. This new state-of-the-art facility is three times our current area and enables us to keep up with the demand for our services, providing biologically relevant target engagement data to drug discovery and development clients worldwide.

The move to the new facility is expected to occur in late Q4, 2021, preparing the company for further scaling up our service offerings in 2022. By being an active partner in the Life Science community the company will further strengthen and develop its position as a leader in cutting edge drug discovery.

“We have experienced a very strong growth since incorporating the company, and we take great pride in knowing our customers are bringing new medicines to market more quickly thanks to our help. We are very excited about this move, investing in the future of Pelago, to increase our customers accessibility to our expertise in drug discovery, focusing on the patented CETSA® technology” - Michael Dabrowski, CEO

#### **For more information**

Pelago Bioscience AB: Michael Dabrowski, CEO, Tel. +46 (0)730 715 334,  
[michael@pelagobio.com](mailto:michael@pelagobio.com)

#### **About Pelago Bioscience AB:**

Spun out from the Karolinska Institute, Stockholm Sweden, Pelago Bioscience AB (<http://pelagobio.com>) was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. This reduces time and money spent on the non-optimal compounds and allows faster development of more efficacious new drugs.